CARPL.ai to Provide Resonance Health Products through its Global Installations

Highlights

- Platform Integration & Partnership Agreement signed with CARPL.ai Inc.

- CARPL.ai provides a unique platform connecting PACS to medical imaging AI solutions

- Platform allows healthcare providers to access, assess + integrate AI in radiology workflows

- FerriSmart® and HepaFat-AI® medical devices to be deployed on CARPL.ai global installations

Resonance Health Contracts with CARPL.ai

Resonance Health Ltd (ASX: RHT) ("Resonance Health" or "Company") has entered into a Platform Integration & Partnership Agreement ("Agreement") with CARPL.ai Inc. ("CARPL.ai"), a Delaware corporation that provides a unique platform connecting PACS to artificial intelligence ("AI") software medical devices ("SaMD"). Picture Archiving & Communication Systems ("PACS") is medical imaging technology used globally by medical centers and clinicians to manage medical images.

The Agreement enables Resonance Health to deliver its FerriSmart® and HepaFat-AI® software medical devices through CARPL.ai's global installations. It provides CARPL.ai with a revocable, non-exclusive, licence to access FerriSmart® and HepaFat-AI® for the benefit of CARPL.ai users in agreed territories where CARPL.ai has been deployed at leading medical and research institutions, including the USA, Brazil, India, Canada, and Australia. Resonance Health's devices will be held in a cloud environment administered and controlled by Resonance Health, and de-identified data will be exchanged between CARPL.ai and Resonance Health through secure transfer methodology.

FerriSmart® and HepaFat-AI® will be accessible to CARPL.ai clinicians and medical imaging users by way of the CARPL - Caring Analytics Platform ("Platform"), which allows healthcare professionals in clinical and research settings to analyse multi-modal imagery (X-ray, CT, MRI scans) using either standard methods or with AI-assisted solutions. The Platform allows users to compare their current imaging diagnosis methods with AI SaMD solutions, comparing results and performance in real-time. In addition to being an attractive validation technique for clinicians, these features are helpful to research institutions for use in connection with clinical trials.

CARPL.ai will be compensated by way of commissions on sales achieved through its Platform. Pricing for FerriSmart® and HepaFat-AI® is country specific and is changeable on 90 days' notice to CARPL.ai, and in any event, on an annual basis as part of the Company's annual review of its global product list pricing. Sales proceeds are collected by CARPL.ai and paid to Resonance Health (less CARPL.ai's commission) each month. The Agreement term is three years but may be terminated without cause by either party on 90 days' notice. Resonance Health must respond to CARPL.ai users within agreed timeframes regarding queries about FerriSmart® or HepaFat-AI® and both parties have agreed to strict confidentiality and privacy measures in respect of patient health information.

About CARPL.al

CARPL.ai is the world's first testing and deployment platform for medical imaging AI applications, which connects healthcare providers to third party AI applications, helping improve access, affordability and quality of medical care. CARPL.ai data management tools, AI marketplace, annotation and validation modules are used by some of the world's leading healthcare providers, AI researchers, industry teams and startups.

CARPL.al & Resonance Health Comment

CARPL.ai Chief Executive Officer, Dr. Vidur Mahajan, commented:

"At CARPL, our vision is to provide healthcare providers a seamless, unified experience across the entire ecosystem of AI developers globally. Our partnership with Resonance Health, a company we have looked up to for many years, is another step in this direction. Resonance Health's solutions are truly unique, and we hope to implement them across our user-base across the world.

With the AI ecosystem, and thereby the number of AI applications for radiology, growing at an exponential pace, it is nearly impossible for hospitals and imaging centres to have techno-commercial relationships with 10s, if not 100s of developers of AI solutions. CARPL serves as the single integration layer between healthcare providers and AI developers.

Apart from clinical deployment, we also intend to help Resonance Health run validation studies for their algorithms. We have run several clinical trials for AI, for FDA and CE approval of these AI."

Resonance Health Managing Director, Mr. Michell Wells, commented:

"The partnership with CARPL.ai greatly enhances our service delivery into markets such as India, Brazil, USA, Australia, and Canada. We are delighted to work with the highly skilled CARPL.ai team to deliver our AI medical devices to their customers globally. The CARPL.ai team has created an intelligent platform that integrates SaMD into PACS and clinician workflows.

This opportunity also utilizes our new delivery methodology for our AI services, which sees us moving away from on-premises deployment to controlled cloud-hosting of our devices. This enables a singular master version of all our devices to be held in a Company administered and controlled cloud environment. This is a superior solution and vastly more scalable and cost effective than multiple on-premises deployments.

This new architecture is a recent evolution by our developers providing greater control of our products and intellectual property. The cloud hosted deployment model allows a single, tightly controlled centralised version of the medical devices to be quickly onboarded and simultaneously accessed by multiple users, including channel partners, medical imaging centers and hospitals."

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd.

For further information please contact:

Mitchell Wells
Managing Director, Resonance Health Ltd
E: mitchellw@resonancehealth.com
P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company, specialising in the development and delivery of non-invasive medical imaging software and services.

The Company's products are used globally by clinicians in the diagnosis and management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing high quality quantitative measurements essential in the diagnosis and management of diseases.

Resonance Health's dedication to scientific rigour and quality management has enabled it to achieve regulatory clearances for a range of Software as a Medical Device (**SaMD**) products in the USA, Europe and Australia and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Some of the SaMD products incorporate the use of Artificial Intelligence (**AI**):

- **FerriScan®** a core-lab product that provides accurate measurement of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.

- **FerriSmart®** an AI-driven, non-invasive MRI-based device for the automated real-time measurement of LIC in patients.

- **HepaFat-AI®** an AI-driven, non-invasive MRI-based device for the automated real-time multi-metric measurement of liver fat in patients, for use in the assessment of individuals with confirmed or suspected fatty liver disease.

- **LiverSmart®** an AI-driven, non-invasive MRI-based multi-parametric device that combines FerriSmart® and HepaFat-AI® into a consolidated report that provides accurate measurement of liver iron concentration <u>and</u> liver fat.

- **CardiacT2*** the most widely accepted MRI-based method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* has regulatory clearance from the TGA and CE marking.

The Company has an active development pipeline of additional medical imaging analysis products and services, including, **LungSmart**® and **Alert-PE™**; AI tools for the automated review of chest CT scans of patients with cystic fibrosis and suspected pulmonary embolism, respectively.

Stakeholders including clinicians and patients are encouraged to follow Resonance Health on Facebook, LinkedIn, and Twitter.

FOLLOW US

in		f
/Resonance-Health-Ltd	/ResonanceHealth	/ResonanceHealthLtd